Life Sciences Seminar Series LSSS 2011-2012 in Geneva


Lectures are at 4pm in Hall A100 Sciences II 30 quai Ernest Ansermet, Geneva

17.10.2011 Benjamin GEIGER
The molecular basis for the mechanical activation of integrin adhesions

08.11.2011 Patrick CRAMER
Gene transcription: molecular movies and regulatory systems

22.11.2011 Naama BARKAI
Scaling pattern with size during the development of multicellular organisms

13.12.2011 Jacques PROST
Physical theory for biology

28.02.2012 Jonathan WEISSMAN
Biology without bias: new tools for probing biological systems

06.03.2012 Enrico COEN
From genes to shape

20.03.2012 Jürgen KNOBLICH
Asymmetric cell division and tumorigenesis in neural stem cell lineages

27.03.2012 Bruno AMATI
Epigenome analysis in Myc-driven tumors

08.05.2012 Howy JACOBS
Alternative respiratory chain enzymes: An evolutionary curiosity, or the cure for all known diseases?

22.05.2012 Robert A. MARTIENSSEN
Heterochromatin reprogramming, RNA interference and germ cell fate

26.06.2012 John MATTICK
RNA: the computational engine of development and cognition

03.07.2012 Nicole KING
Choanoflagellates, colonies, and the origin of animals

Fri-Sun Sept 17-19, 2010 2nd AnEUploidy Workshop Split Croatia; co-organizer: A.Reymond

”AnEUploidy” is the acronym of an Integrated Project (IP) funded by the European Commission within its Sixth Framework Programme under the thematic area “Life sciences, genomics and biotechnology for health”. This four years long project aims to contribute to the understanding of the molecular basis and pathogenic mechanisms of aneuploidies (see It is coordinated by Stylianos E. Antonarakis from the University of Geneva Medical School, Switzerland and groups the multidisciplinary skills of 18 European and Israeli research groups. With the aim of furthering the primary objectives of this project, the members of this consortium plan to organise twice during its lifetime an international workshop. The second of these AnEUploidy workshops will be held in Split, Croatia, September 17-19, 2010 and organized by Alexandre Reymond & Dean Nižetić. It will also include 13 eminent invited speakers, outside the consortium. It should allow the members of the aneuploidy/CNV community to share views, progress, and ideas. It will also include a half day lay language presentations to Down syndrome associations, health specialists and parents. See also :

Fri Sep 3, 2010 SKMB Meeting 10:00 GEN

SKMB Gene Regulation Workshop


Nouria Hernandez
François Karch
Françoise Stutz

Program preview:

Wendy Bickmore (MRC, Edinburgh)
James Goodrich (University of Colorado, Boulder)
Edith Heard (Institut Curie, Paris)
Tom Maniatis (Columbia University Medical Center, New York)
Danesh Moazed (Harvard Medical School, University, Boston)
Steve Smale (University of California, Los Angeles)
Didier Trono (EPFL, Lausanne)

see also :

GEN Auditorium C

Mon Apr 12, 2010 BIG Sem. P.Cosson BIO

BIG seminar

April 12 17:00 Biophore

Pierre Cosson

University of Geneva

Interaction of cells with bacteria: how little we know

Eukaryotic cells and bacteria constantly interact, both in the environment and within our body. Phagocytic eukaryotic cells ingest and kill bacteria, either to feed upon them or to eliminate them from our organism. Bacteria exhibit a vast array of mechanisms that allow them to resist phagocytic cells,and to infect multicellular organisms. The mechanisms by which phagocytic cells kill bacteria, as well as the mechanisms by which bacteria escape killing are key elements of this confrontation, and are still poorly understood. We are making use of Dictyostelium amoebae, a model phagocytic cell amenable to genetic analysis to try to unravel this complex interplay.Looking forward to welcoming you at this BIG seminar.

B.Thorens “Innovative Medicines Initiative” project leader

B.Thorens is the leader of an IMI project on diabetes, a collaboration between 15 research groups from different european countries and 8 pharmaceutical industries.

Innovative Medicines Initiative”  is a unique partnership between the European Community and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

The aim of IMI is to to support the faster discovery and development of better medicines for patients and to enhance Europe’s competitiveness by ensuring that its biopharmaceutical sector remains a dynamic high-technology sector.

2 other swiss groups participate in this project on diabetes, one from the UNIGE and one from the SIB (I.Xenarios).